Endpoints News 生物医药· Lei Lei Wu·· 4 小时前AI 评分40
Erasca 和 Alterome 在 KRAS 会议上的竞争态势
KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach
AI 导读
Erasca 在 KRAS 会议上展示了其胰腺癌药物的强劲数据,而 Revolution Medicines 也在同一会议上发布了积极结果。竞争正在加剧。
正文
Revolution Medicines posted strong data on its targeted pancreatic cancer drug Thursday evening, but competition is building at every turn in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news